Hematopoietic and Lymphatic System Neoplasm

In an in vitro study, a Ba/F3 murine cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 33.… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In an in vitro kinase study, the recombinant ABL1 Q252H mutant kinase did not demonstrate resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 0 and 0) when compared to wil… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In an in vitro study, a Ba/F3 cell line expressing a Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (3.4 nmol/L vs. 0.8 nmol/L… (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: … (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the Q252H mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have increased sensitivity to dasatinib treatment, as compa… (full text at CIViC)

PMID 15256671 · Shah et al., 2004 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In an in vitro kinase study, the recombinant ABL1 Q252H mutant kinase did not demonstrate resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: -1 and 0) when compared to wi… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In an in vitro study, stochastic mutations in the ABL1 region of a stably expressed p210 BCR-ABL fusion were generated in Ba/F3 cell lines from five independently derived, mutagenized libraries. Dasat… (full text at CIViC)

PMID 15705718 · Burgess et al., 2005 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A chronic-phase (CP) patient achieved a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In two cell-based studies, a panel of either 18 or 16 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations … (full text at CIViC)

PMID 15930265 · O'Hare et al., 2005 · Open in CIViC

A panel of 18 mutations representing 85% of known mutations seen in imatinib CML patents were used to evaluate the effectiveness of drug binding. All mutations were compared with non-mutated BCR-ABL p… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. A late-chronic phase (CP) patient had a complete… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In an in vitro study, a KBM-5 cell line expressing T315I mutation in the ABL1 portion of the BCR-ABL fusion protein (overexpression) demonstrated sensitivity to axitinib treatment, comparable to KBM-5… (full text at CIViC)

PMID 26912052 · Halbach et al., 2016 · Open in CIViC

In an in vitro study, primary tumor cells from 2 chronic myeloid leukemia patients (endogenous) and pro-B Ba/F3 cells (overexpression) harboring T315I mutation in the ABL1 portion of the BCR-ABL1 fusi… (full text at CIViC)

PMID 26239229 · Okabe et al., 2015 · Open in CIViC

In an in vitro study, pro-B Ba/F3 cell line expressing T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein (overexpression) demonstrated increased sensitivity to axitinib treatment (IC50… (full text at CIViC)

PMID 26582647 · Zabriskie et al., 2016 · Open in CIViC

Bone marrow mononuclear cells (BM MNCs) were isolated from three acute lymphoblastic leukemia patients with the BCR-ABL1 T315I variant who were pretreated with various chemotherapeutics and dasatinib.… (full text at CIViC)

PMID 25686603 · Pemovska et al., 2015 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In an in vitro study, a Ba/F3 murine cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to bosutinib treatment (I… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

This is a retrospective study of imatinib-resistant (n = 805) or -intolerant (n = 238), chronic myeloid leukemia (chronic-phase), patients with mutations in the BCR-ABL gene fusion kinase domain from … (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the T315I mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=13) were associated with acquired resistant t… (full text at CIViC)

PMID 27485109 · Soverini et al., 2016 · Open in CIViC

Prior to dasatinib treatment, two imatinib-resistant patients with chronic myeloid leukemia in accelerated phase had the BCR-ABL1 fusion with the T315I secondary variant in 8/10 and 10/10 bacterial cl… (full text at CIViC)

PMID 16775234 · Talpaz et al., 2006 · Open in CIViC

In a retrospective study (of phase 3 clinical trial NCT00481247) of 363 Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia patients in chronic phase, patients with the T315I mutation in t… (full text at CIViC)

PMID 26118315 · Hughes et al., 2015 · Open in CIViC

In a retrospective study of 45 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL fusion positive (Ph+) chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia (ALL) patients, pati… (full text at CIViC)

PMID 17339191 · Soverini et al., 2007 · Open in CIViC

In a retrospective study of 174 imatinib-resistant or -intolerant Philadelphia chromosome BCR-ABL1 fusion positive accelerated phase chronic myeloid leukemia patients, patients with the T315I mutation… (full text at CIViC)

PMID 19487385 · Apperley et al., 2009 · Open in CIViC

In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In an in vitro kinase study, the recombinant ABL1 H396P mutant kinase did not demonstrate resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 0 and 1) when compared to wil… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In an in vitro study, a KBM-5 cell line expressing T315I mutation in the ABL1 portion of the BCR-ABL fusion protein (overexpression) demonstrated resistance to dasatinib treatment, compared to KBM-5 c… (full text at CIViC)

PMID 26912052 · Halbach et al., 2016 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with reduced sensitivity to dasatinib treatment (IC50: 1… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the T315I mutation in the ABL1 portion of the BCR-ABL1 fusion protein was found to have reduced sensitivity to dasatinib treatment, comparable… (full text at CIViC)

PMID 15256671 · Shah et al., 2004 · Open in CIViC